The therapeutic potential of antisense oligonucleotides

BioEssays

Volumn 17, Issue 12, 1995, Pages 1055-1063

  Sharma, Harsh W ^a   Narayanan, Ramaswamy ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; NEOPLASM; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; CLINICAL TRIALS; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER;

ANIMALIA;

EID: 0029608635     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.950171210     Document Type: Article

References (72)

1. Specific regulation of gene expression by antisense, sense and antigene nucleic acids
2. Oligonucleoside methylphosphonates as antisense reagents
3. Phosphorothioate oligodeoxynucleotide analogues
4. Antisense inhibition of ras p21 expression that is sensitive to a point mutation
5. Down‐regulation of c‐MYC antigen expression in lymphocytes of Emu‐c‐myc transgenic mice treated with anti‐c‐myc DNA methylphosphonates
6. Antisense oligonucleotides: a new therapeutic principle
7. Antisense oligonucleotides as therapeutic agents – Is the bullet really magical?
8. Single base discrimination for ribonuclease H‐dependent antisense effects within intact human leukaemia cells
9. Specificity of antisense oligonucleotides in vivo
10. Current concepts in antisense drug design
11. Specific blockade of basic fibroblast growth factor gene expression in endothelial cells by antisense oligonucleotide
12. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate polyethylene glycol
13. In vivo modulation of N‐myc expression by continuous perfusion with an antisense oligonucleotide
14. Antisense c‐myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo
15. Single intraluminal delivery of antisense cdc2 kinase and proliferating‐cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia
16. In vivo treatment of human leukemia in a scid mouse model with c‐myb antisense oligodeoxynucleotides
17. Biologic and therapeutic significance of MYB expression in human melanoma
18. Ablation of transplanted HTLV‐1 tax‐transformed tumors in mice by antisense inhibition of NF‐κB
19. Antisense inhibition of the p65 subunit of NF‐κB blocks tumorigenicity and causes tumor regression
20. Evidence for differential functions of the p50 and p65 subunits of NF‐κB using a cell adhesion model
21. Antisense oligonucleotides to the p65 subunit of NF‐κB block CD11b expression and alter adhesion properties of differentiated HL‐60 granulocytes
22. Regulation of adhesion and growth of fibrosarcoma cells by rel A NF‐κB involves TGFb
23. Antisense therapy of cancer
24. Sequence context of antisense RelA/NF‐κB phosphorothioates determines specificity
25. Antisense DNA inhibition of tumor growth induced by c‐Ha‐ras oncogene in nude mice
26. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha‐ras mediated cell proliferation and tumorigenicity in nude mice
27. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides
28. Antisense oligodeoxynucleotides to NMDA‐R1 receptor channel to protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions
29. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates
30. Antisense oligodeoxynucleotide inhibits D2 dopamine receptor‐mediated behavior and D2 messenger RNA
31. In vivo toxicologic effects of rel A antisense phosphorothioates in CD‐1 mice
32. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion
33. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey
34. Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey
35. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a Phase I trial
36. Pharmacokinetics of an anti‐HIV antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV‐infected subjects
37. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs
38. Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies
39. A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF‐κB p65 causes sequence‐specific immune stimulation
40. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV‐I
41. CpG motifs in bacterial DNA trigger direct B‐cell activation
42. Gene inhibition using antisense oligodeoxynucleotides
43. Antisense oligonucleotides
44. Sequence independent induction of Sp‐1 transcription factor by phosphorothioate oligodeoxynucleotides
45. The antiproliferative activity of c‐myb and c‐myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism
46. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides
47. BCL2‐mediated tumorigenicity of a human T‐lymphoid cell line: synergy with MYC and inhibition of BCL2 antisense
48. Investigations of antisense oligonucleotides targeted against bcl‐2 RNAs
49. Inducible production of c‐fos antisense RNA inhibits 3T3 cell proliferation
50. Selective inhibition of mutant Ha‐ras mRNA expression by antisense oligonucleotides
51. Selective inhibition of leukemia cell proliferation by BCR‐ABL antisense oligonucleotides
52. Antisense RNA to the putative tumor‐suppressor gene DCC transforms Rat‐1 fibroblasts
53. The involvement of ‘tumor suppressor’ p53 in normal and chronic myelogenous leukemia hemopoiesis
54. Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes
55. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor
56. Insulin‐like growth factor‐I (IGF‐I) antisense oligodeoxynucleotide mediated inhibition of DNA synthesis by WI‐38 cells: evidence for autocrine actions of IGF‐I
57. Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides
58. The secondary antigen‐specific IgE response in murine lymphocytes is resistant to blockade by anti‐IL4 antibody and an antisense oligodeoxynucleotide for IL4 mRNA
59. Interleukin‐6 functions as an intracellular growth factor in hairy cell leukemia in vitro
60. Extension of the life‐span of human endothelial cells by an interleukin‐1a antisense oligomer
61. Interleukin‐11 acts as an autocrine growth factor for human megakaryoblastic cell lines
62. Specific repression of granulocyte‐macrophage and granulocyte colonystimulating factor gene expression in interleukin‐1‐stimulated endothelial cells with antisense oligodeoxynucleotides
63. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
64. Transient requirement for vimentin in neuritogenesis: intracellular delivery of anti‐vimentin antibodies and antisense oligonucleotides inhibit neurite initiation but not elongation of existing neurites in neuroblastoma
65. Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides
66. Inhibition of human immunodeficiency virus by using an oligonucleoside methylphosphonate targeted to the tat‐3 gene
67. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells
68. Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre‐mRNAs 4 and 5
69. Mechanisms of inhibition of herpes simplex virus type 2 growth by 28‐mer phosphorothioate oligodeoxycytidine
70. Antisense phosphorothioate oligonucleotides: selective killing of the intracellular parasite Leishmania amazonensis
71. Short modified antisense oligonucleotides directed against Ha‐ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation